Valuation : NetraMark Holdings Inc.

Market Cap 6.15Cr 4.45Cr 3.83Cr 3.6Cr 3.29Cr 419.75Cr 6.17Cr 43Cr 17Cr 215.36Cr 17Cr 16Cr 693.79Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 6.15Cr 4.45Cr 3.83Cr 3.6Cr 3.29Cr 419.75Cr 6.17Cr 43Cr 17Cr 215.36Cr 17Cr 16Cr 693.79Cr EV / Sales 2026 *
153x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
1 day+1.56%
1 week-4.41%
Current month+1.56%
1 month-12.16%
3 months-23.53%
6 months-29.35%
Current year-40.91%
1 week 0.63
Extreme 0.63
0.67
1 month 0.6
Extreme 0.6
0.75
Current year 0.59
Extreme 0.59
1.28
1 year 0.59
Extreme 0.59
1.66
3 years 0.16
Extreme 0.155
1.8
5 years 0.15
Extreme 0.15
1.97
10 years 0.15
Extreme 0.15
3.17
Manager TitleAgeSince
Chief Executive Officer - 17/02/2022
President - 04/07/2022
Director of Finance/CFO 57 18/07/2022
Director TitleAgeSince
Chairman 40 09/06/2025
Director/Board Member - -
Director/Board Member - 16/06/2022
Date Insider Type Main position Quantity % Market Cap. Importance
25/08/26 Buy

Director

30,000 0.0323%
25/08/26 Buy

Director

2,000 0.0022%
25/08/26 Buy

Director

14,500 0.0156%
Change 5-day change 1-year change 3-year change Capi.($)
+1.56%-4.41%-60.37%+140.74% 4.45Cr
-2.04%-2.69%+0.95%+50.11% 3,71100Cr
-4.49%-6.42%+13.86%+1,039.41% 42TCr
-3.99%-14.01%-16.61%+18.65% 8.06TCr
-0.85%-10.15%+56.47%+118.03% 7.65TCr
-5.40%-11.02%-34.16%-15.43% 7.55TCr
-0.89%-6.09%-41.50%+185.80% 6.87TCr
-2.62%-0.44%+9.95%-8.15% 4.8TCr
+0.26%-8.79%-10.43%+52.29% 4.01TCr
-3.12%-2.02%+114.39%+252.57% 3.58TCr
Average -2.16%-6.60%+3.26%+183.40% 45.55TCr
Weighted average by Cap. -2.31%-3.57%+2.42%+143.65%

Financials

2026 *2027 *
Net sales 4L 3L 2L 2L 2L 2.74Cr 4L 27.72L 10.76L 1.4Cr 10.88L 10.64L 4.52Cr -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-
Date Price Change Volume
04/26/04 CA$0.6500 +1.56% 16,500
03/26/03 CA$0.6400 -3.03% 14,500
02/26/02 CA$0.6600 +1.54% 44,102
01/26/01 CA$0.6500 +1.56% 9,515
31/26/31 CA$0.6400 -5.88% 24,073

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AIAI Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!